AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35500171 — intervention group
Group type: COMPARATOR
Intervention: Aspirin without PPIs
Number of subjects: 15839
Study 34214585 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg tablets once daily for 12 weeks
Number of subjects: 52
Study 34214585 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets once daily for 12 weeks
Number of subjects: 52
Study 36345889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 24
Study 36345889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 24
Study 36345889 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic participants)
Number of subjects: 24
Study 34416879 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily for six months)
Number of subjects: 175
Study 34416879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 33028425 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted hypothermia with a target temperature of 33 °C
Number of subjects: 1900
Study 33028425 — intervention group
Group type: COMPARATOR
Intervention: Targeted normothermia and active treatment of fever (≥ 37.8 °C)
Number of subjects: 1900
Study 35858836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2)
Number of subjects: 8
Study 35858836 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (21% O2)
Number of subjects: 8
Study 34622702 — intervention group
Group type: EXPERIMENTAL
Intervention: High anticipated regret
Number of subjects: 340
Study 34622702 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable attitudes toward consequences of screening
Number of subjects: 340
Study 34622702 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about pain
Number of subjects: 340
Study 34622702 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about invasion of privacy
Number of subjects: 340
Study 35659580 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 160
Study 35659580 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 160
Study 32544609 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 21
Study 32544609 — intervention group
Group type: COMPARATOR
Intervention: FMISO-PET
Number of subjects: 21
Study 36059956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic TXA (10 mg/kg followed by 5 mg/kg/h) with TEG‐guided hemostatic algorithm
Number of subjects: 83
Study 36059956 — intervention group
Group type: COMPARATOR
Intervention: Conventional coagulation management
Number of subjects: 83
Study 36059956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic TXA with TEG‐guided hemostatic algorithm
Number of subjects: 83
Study 32817692 — intervention group
Group type: EXPERIMENTAL
Intervention: Tsima intervention (HIV treatment as prevention)
Number of subjects: 1189
Study 32817692 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 1189
Study 36046991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Interval Training (LIIT)
Number of subjects: 36
Study 36046991 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 36
Study 36046991 — intervention group
Group type: COMPARATOR
Intervention: Control (CNT)
Number of subjects: 36
Study 35864547 — intervention group
Group type: EXPERIMENTAL
Intervention: HOGO bed (intervention group)
Number of subjects: 18
Study 35864547 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control group)
Number of subjects: 18
Study 33534905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular Matrix (a mixture of a-PRP and HA)
Number of subjects: 93
Study 33534905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 93
Study 33534905 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma (a-PRP)
Number of subjects: 93
Study 32060155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-based elixir mouthwash (10 mL 0.1 mg/mL; swish for 2 min and spit, four times daily for 9 weeks)
Number of subjects: 120
Study 32060155 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care
Number of subjects: 120
Study 32060155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-based elixir mouthwash
Number of subjects: 120
Study 34654569 — intervention group
Group type: EXPERIMENTAL
Intervention: Slush Nitrogen (SN)
Number of subjects: 556
Study 34654569 — intervention group
Group type: COMPARATOR
Intervention: Liquid Nitrogen (LN)
Number of subjects: 556
Study 36506010 — intervention group
Group type: EXPERIMENTAL
Intervention: SbV + NAC
Number of subjects: 60
Study 36506010 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC treatment of SLA-stimulated PBMCs
Number of subjects: 60
Study 36506010 — intervention group
Group type: COMPARATOR
Intervention: SbV
Number of subjects: 60
Study 32474302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (pitavastatin + ezetimibe)
Number of subjects: 0
Study 32474302 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional lipid-lowering therapy (pitavastatin monotherapy)
Number of subjects: 0
Study 32474302 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3, HDL-C ≥53.6 mg/dL)
Number of subjects: 0
Study 32474302 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of Groups 1 and 3
Number of subjects: 0
Study 32474302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin + ezetimibe therapy
Number of subjects: 0
Study 32474302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin monotherapy
Number of subjects: 0
Study 35238491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amplitude WBV (LO)
Number of subjects: 40
Study 35238491 — intervention group
Group type: COMPARATOR
Intervention: High-amplitude WBV (HI)
Number of subjects: 40
Study 33554032 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TNM (mTNM) classification
Number of subjects: 45379
Study 33554032 — intervention group
Group type: COMPARATOR
Intervention: AJCC 8th TNM classification
Number of subjects: 45379
Study 33339359 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing energy shot (CAF, 5 mg/kg)
Number of subjects: 20
Study 33339359 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated energy shot (DECAF)
Number of subjects: 20
Study 35986400 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean Cut intervention (modifying and implementing the WHO Surgical Safety Checklist, process mapping, site-specific action plans, targeted training)
Number of subjects: 8100
Study 35986400 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean Cut intervention
Number of subjects: 8100
Study 34860351 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D combined with clomiphene citrate
Number of subjects: 0
Study 34860351 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32721973 — intervention group
Group type: EXPERIMENTAL
Intervention: Early spot urinary sodium (UNa)
Number of subjects: 160
Study 32721973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic efficiency
Number of subjects: 160
Study 36433919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment (target 110 to <130 mmHg)
Number of subjects: 3989
Study 36433919 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP treatment (target 130 to <150 mmHg)
Number of subjects: 3989
Study 36433919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment
Number of subjects: 3989
Study 36433919 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP treatment
Number of subjects: 3989
Study 33225631 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg IV every 4 weeks, reduced to 300 mg every 4 weeks based on benefit/risk profile
Number of subjects: 246
Study 33225631 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 246
Study 32768393 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 66
Study 36184780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 48
Study 36184780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 48
Study 36184780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 48
Study 36184780 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 48
Study 33961176 — intervention group
Group type: EXPERIMENTAL
Intervention: FIND intervention group
Number of subjects: 91
Study 33961176 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 91
Study 35182101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean pork (156 g day-1)
Number of subjects: 36
Study 35182101 — intervention group
Group type: COMPARATOR
Intervention: Chicken (active-control, 156 g day-1)
Number of subjects: 36
Study 35182101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean pork
Number of subjects: 36
Study 35182101 — intervention group
Group type: COMPARATOR
Intervention: Chicken
Number of subjects: 36
Study 35182101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean pork and Chicken
Number of subjects: 36
Study 33793146 — intervention group
Group type: EXPERIMENTAL
Intervention: Khār-i-khasak (Tribulus terrestris Linn.)
Number of subjects: 100
Study 33793146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36086767 — intervention group
Group type: EXPERIMENTAL
Intervention: AP‐IMRT with MSA of 4-50 cm2
Number of subjects: 10
Study 32816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (b.d.) induction therapy
Number of subjects: 0
Study 32816215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d. maintenance therapy
Number of subjects: 0
Study 32816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib Overall cohort
Number of subjects: 0
Study 32816215 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib-treated patients with rheumatoid arthritis
Number of subjects: 0
Study 32816215 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib-treated patients with psoriasis
Number of subjects: 0
Study 32816215 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib-treated patients with psoriatic arthritis
Number of subjects: 0
Study 35781465 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction Comprehensive Health Enhancement Support System app
Number of subjects: 0
Study 35781465 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling
Number of subjects: 0
Study 35188552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Number of subjects: 321
Study 35188552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 321
Study 35188552 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 321
Study 34485096 — intervention group
Group type: EXPERIMENTAL
Intervention: Op Koers Online (N = 35)
Number of subjects: 59
Study 34485096 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (N = 24)
Number of subjects: 59
Study 34910595 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg, twice daily for 2 months
Number of subjects: 12
Study 34910595 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 12
Study 34910595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32049283 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable valve (SEV) - Evolut R, Medtronic Inc.
Number of subjects: 447
Study 32049283 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable valve (BEV) - Sapien 3, Edwards Lifesciences
Number of subjects: 447
Study 35182418 — intervention group
Group type: EXPERIMENTAL
Intervention: MIB-626 1000 mg once daily
Number of subjects: 32
Study 35182418 — intervention group
Group type: EXPERIMENTAL
Intervention: MIB-626 1000 mg twice daily
Number of subjects: 32
Study 35182418 — intervention group
Group type: EXPERIMENTAL
Intervention: MIB-626 (both dosages)
Number of subjects: 32
Study 35182418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32816504 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SIB (Treatment for Self-Injurious Behaviors)
Number of subjects: 33
Study 32816504 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 33
Study 36098938 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS combined with TAPB (group NTG)
Number of subjects: 90
Study 36098938 — intervention group
Group type: COMPARATOR
Intervention: TAPB (group NG)
Number of subjects: 90
Study 33232752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial oxygen tension (PaO2) between 100 and 180 mmHg
Number of subjects: 491
Study 33232752 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial oxygen tension (PaO2) <100 mmHg
Number of subjects: 491
Study 33232752 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial oxygen tension (PaO2) >180 mmHg
Number of subjects: 491
Study 35679043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation treatment (up to 11 counseling sessions with free medications)
Number of subjects: 0
Study 35679043 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (up to 4 counseling sessions with medication advice)
Number of subjects: 0
Study 35679043 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral to the state quitline)
Number of subjects: 0
Study 33582566 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 417
Study 33582566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 417
Study 33582566 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 417
Study 33582566 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since diagnosis
Number of subjects: 417
Study 33582566 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 417
Study 33582566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors
Number of subjects: 417
Study 36383611 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.2 mg on day 1 followed by 0.6 mg daily for 13 days)
Number of subjects: 300
Study 36383611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 36383611 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 300
Study 35607981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) exercise intervention for 6 months
Number of subjects: 619
Study 35607981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-Moderate Intensity (LMI) exercise intervention for 6 months
Number of subjects: 619
Study 35607981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (HI and LMI combined)
Number of subjects: 619
Study 35607981 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity (HI) exercise
Number of subjects: 619
Study 35607981 — intervention group
Group type: COMPARATOR
Intervention: Low-to-Moderate Intensity (LMI) exercise
Number of subjects: 619
Study 35607981 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 619
Study 33930620 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) education program, 5 home visits over 3 months
Number of subjects: 60
Study 33930620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 33930620 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) education program
Number of subjects: 60
Study 32347805 — intervention group
Group type: COMPARATOR
Intervention: Key-in‐based aid (KBA)
Number of subjects: 124
Study 32347805 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo‐based aid (PBA)
Number of subjects: 124
Study 32347805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture‐based aid (GBA)
Number of subjects: 124
Study 35179802 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of intermittent fasting
Number of subjects: 0
Study 35179802 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 32249621 — intervention group
Group type: EXPERIMENTAL
Intervention: Kd70 QW (carfilzomib 70 mg/m2 once-weekly plus dexamethasone)
Number of subjects: 0
Study 32249621 — intervention group
Group type: COMPARATOR
Intervention: Kd27 BIW (carfilzomib 27 mg/m2 twice-weekly plus dexamethasone)
Number of subjects: 0
Study 35093547 — intervention group
Group type: EXPERIMENTAL
Intervention: No hip precautions (NP)
Number of subjects: 346
Study 35093547 — intervention group
Group type: COMPARATOR
Intervention: Hip precautions (HP)
Number of subjects: 346
Study 35093547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NP and HP)
Number of subjects: 346
Study 34772395 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-tailored polyethylene mesh
Number of subjects: 27
Study 34772395 — intervention group
Group type: COMPARATOR
Intervention: Traditional TOT mesh
Number of subjects: 27
Study 35429893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 9239
Study 35429893 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 9239
Study 35429893 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially eligible patients
Number of subjects: 9239
Study 35429893 — intervention group
Group type: COMPARATOR
Intervention: Various RCTs
Number of subjects: 9239
Study 32748229 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic classification system for adult idiopathic scoliosis
Number of subjects: 30
Study 34408026 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions led by trained facilitators
Number of subjects: 0
Study 34408026 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study 32597737 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Cognitive Affective Therapy (ICAT-BED)
Number of subjects: 78
Study 32597737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy Guided Self-Help (CBTgsh)
Number of subjects: 78
Study 32597737 — intervention group
Group type: COMPARATOR
Intervention: Both ICAT-BED and CBTgsh
Number of subjects: 78
Study 34288280 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCT + treatment as usual (TAU)
Number of subjects: 90
Study 34288280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) + TAU
Number of subjects: 90
Study 34288280 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 90
Study 32521022 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided customized ablation treatment (TCAT)
Number of subjects: 23
Study 32521022 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) photorefractive keratectomy (PRK)
Number of subjects: 23
Study 32143657 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA-HTN intervention
Number of subjects: 16
Study 32143657 — intervention group
Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 16
Study 33962825 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cancer anxiety, being male, recent screening, family history of breast/prostate cancer, independence in activities of daily living
Number of subjects: 271
Study 33962825 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly reported reasons for intending to continue screening
Number of subjects: 271
Study 36286097 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 5982
Study 36286097 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 5982
Study 33884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10mg b.d. retreatment
Number of subjects: 0
Study 36241697 — intervention group
Group type: EXPERIMENTAL
Intervention: 6xR-CHOP + 2R in iPET-negative patients with high mean-SUVAI
Number of subjects: 0
Study 36241697 — intervention group
Group type: EXPERIMENTAL
Intervention: (R-)CHOP in iPET-positive patients with high mean-SUVAI
Number of subjects: 0
Study 36241697 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with CHOP (plus rituximab in CD20-positive lymphomas)
Number of subjects: 0
Study 33157308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigh breath (35 cmH2O pressure‐controlled breath over 4 s, once per minute)
Number of subjects: 20
Study 33157308 — intervention group
Group type: COMPARATOR
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 20
Study 33157308 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 20
Study 33314388 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosa layer stripping (FLS) technique
Number of subjects: 70
Study 33314388 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 70
Study 34499135 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare case management program (weekly case management from a nurse via telephone and weekly video messages for 3 months)
Number of subjects: 68
Study 34499135 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly social telephone calls)
Number of subjects: 68
Study 34499135 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare case management program
Number of subjects: 68
Study 34499135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 32672795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, or 10 mg/kg every 3 weeks)
Number of subjects: 1558
Study 32672795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF WT melanoma (n=1124)
Number of subjects: 1558
Study 32672795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF V600E/K-mutant melanoma (n=434)
Number of subjects: 1558
Study 32672795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF V600E/K-mutant melanoma with prior BRAFi (n=271)
Number of subjects: 1558